CYP19A1 fine-mapping and Mendelian randomization: Estradiol is causal for endometrial cancer

Australian National Endometrial Cancer Study Group (ANECS)

Research output: Contribution to journalArticlepeer-review

33 Scopus citations


Candidate gene studies have reported CYP19A1 variants to be associated with endometrial cancerandwith estradiol (E2) concentrations.We analyzed2937singlenucleotidepolymorphisms (SNPs) in 6608 endometrial cancer cases and 37 925 controls and report the first genome widesignificant association between endometrial cancer and a CYP19A1 SNP (rs727479 in intron 2, P=4.8×10-11). SNP rs727479 was also among those most strongly associated with circulating E2 concentrations in 2767 post-menopausal controls (P=7.4×10-8). The observed endometrial cancer odds ratio per rs727479 A-allele (1.15, CI=1.11-1.21) is compatible with that predicted by theobservedeffectonE2 concentrations (1.09, CI=1.03-1.21), consistentwith the hypothesis that endometrial cancer risk is driven by E2. From 28 candidate-causal SNPs, 12 co-located with three putative gene-regulatory elements and their risk alleles associated with higher CYP19A1 expression in bioinformatical analyses. For both phenotypes, the associationswith rs727479 were stronger amongwomen with a higher BMI (PinteractionZ0.034 and 0.066 respectively), suggesting a biologically plausible gene-environment interaction.

Original languageEnglish (US)
Pages (from-to)77-91
Number of pages15
JournalEndocrine-Related Cancer
Issue number2
StatePublished - Feb 2016


  • CYP19A1
  • Endometrial cancer
  • Estradiol

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Oncology
  • Endocrinology
  • Cancer Research


Dive into the research topics of 'CYP19A1 fine-mapping and Mendelian randomization: Estradiol is causal for endometrial cancer'. Together they form a unique fingerprint.

Cite this